NCT00518089已完成3 期
A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Allergan
- 入组人数
- 859
- 主要终点
- Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge Up to Day 6
研究概览
简要总结
The study will determine the safety and efficacy of gatifloxacin eye drops in patients with bacterial conjunctivitis
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 1 Year 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinically diagnosed with bacterial conjunctivitis
排除标准
- •Signs and/or symptoms of conjunctivitis for more than 96 hours
- •Signs and/or symptoms suggestive of fungal, viral, or allergic conjunctivitis
- •Clinical diagnosis of chlamydia in either eye
研究组 & 干预措施
Placebo Eye Drops
Placebo Comparator
Placebo Eye Drops
干预措施: placebo eye drops (Drug)
Gatifloxacin 0.5% Eye Drops
Experimental
Gatifloxacin 0.5% Eye Drops
干预措施: Gatifloxacin 0.5% eye drops (Drug)
结局指标
主要结局
Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge Up to Day 6
时间窗: 6 Days
Percentage of patients that achieved clinical success, defined as achievement of a score of zero for both conjunctival hyperemia and conjunctival discharge in the study eye up to Day 6. Conjunctival hyperemia and conjunctival discharge were each assessed on a 4-point severity grade scale (0=none, +1=mild, +2=moderate, +3=severe).
次要结局
- Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge at Day 6(Day 6)
- Percentage of Patients With Microbiological Cure Up to Day 6(6 Days)
- Percentage of Patients With Clinical Improvement of Ocular Signs Up to Day 6(6 Days)
- Percentage of Patients With Clinical Improvement of Ocular Symptoms Up to Day 6(6 Days)
研究者
相似试验
已完成
3 期
A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial ConjunctivitisBacterial ConjunctivitisNCT00509873Allergan578
已完成
4 期
A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial ConjunctivitisBacterial ConjunctivitisNCT00464438Allergan171
已完成
2 期
Safety and Efficacy Study of Gatifloxacin Compared With Ciprofloxacin in Patients With Acute Bacterial Corneal UlcersAcute Bacterial Corneal UlcersBacterial KeratitisNCT00651586Allergan129
终止
3 期
Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial ConjunctivitisBacterial ConjunctivitisNCT01740388Bausch & Lomb Incorporated136
已完成
2 期
Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial ConjunctivitisBacterial ConjunctivitisNCT00972777Bausch & Lomb Incorporated474